- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01227278
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
11 août 2016 mis à jour par: MedImmune LLC
A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia
To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
To evaluate the effect of multiple subcutaneous (SC) doses of benralizumab (MEDI 563) on the rate of moderate-to-severe annualized incidence rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with moderate-to-severe COPD who exhibit eosinophilia (greater than or equal to [>=] 3.0 percent [%] sputum eosinophilia in the previous 12 months or at Screening) in sputum compared to placebo.
Type d'étude
Interventionnel
Inscription (Réel)
421
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Frankfurt, Allemagne
- Research Site
-
Mainz, Allemagne
- Research Site
-
-
-
-
-
Quebec, Canada
- Research Site
-
-
Alberta
-
Calgary, Alberta, Canada
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- Research Site
-
-
-
-
-
Hellerup, Danemark
- Research Site
-
København NV, Danemark
- Research Site
-
Odense C, Danemark
- Research Site
-
Århus C, Danemark
- Research Site
-
-
-
-
-
Barcelona, Espagne
- Research Site
-
Lérida, Espagne
- Research Site
-
Málaga, Espagne
- Research Site
-
Oviedo, Espagne
- Research Site
-
-
-
-
-
Gdańsk, Pologne
- Research Site
-
Kraków, Pologne
- Research Site
-
Warszawa, Pologne
- Research Site
-
Łódź, Pologne
- Research Site
-
-
-
-
-
Cambridge, Royaume-Uni
- Research Site
-
Edinburgh, Royaume-Uni
- Research Site
-
Leicester, Royaume-Uni
- Research Site
-
Manchester, Royaume-Uni
- Research Site
-
-
-
-
California
-
Los Angeles, California, États-Unis
- Research Site
-
-
Georgia
-
Marietta, Georgia, États-Unis
- Research Site
-
-
Illinois
-
Normal, Illinois, États-Unis
- Research Site
-
-
New York
-
Brooklyn, New York, États-Unis
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, États-Unis
- Research Site
-
-
Texas
-
Boerne, Texas, États-Unis
- Research Site
-
Tyler, Texas, États-Unis
- Research Site
-
-
Virginia
-
Richmond, Virginia, États-Unis
- Research Site
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
40 ans à 85 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Subjects aged 40-85 years at the time of Screening
- Written informed consent obtained from the subject prior to performing any protocol related procedures
- Documented history of 1 or more Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
- Current smoker or ex-smoker with a tobacco history of greater than or equal to (>=) 10 pack-years
- Adequate contraception from screening through end of trial
- Able to read and write.
Exclusion Criteria:
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
- Pregnant, breastfeeding, or lactating women
- Known history of allergy or reaction to any component of the investigational product formulation
- History of anaphylaxis to any other biologic therapy
- Donation or transfusion of blood, plasma or platelets within the past 3 months prior to Screening
- Other significant pulmonary disease which in the opinion of the investigator or medical monitor, might compromise the interpretation of the study
- Fever greater than (>) 37.0 degree Centigrade (98.6 degree Fahrenheit) at Screening
- Receipt of any novel investigational medicinal product within 3 months before the first dose of investigational product in this study and through the end of the study
- Seropositive for hepatitis A, hepatitis B surface antigen, hepatitis C, or human immunodeficiency virus 1or 2 (HIV-1 or HIV 2)
- History of alcohol or drug abuse within the past year that required treatment that the investigator felt or medical monitor felt would compromise the study data interpretation
- Past or current malignancy within the past 5 years except adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than 1 year prior to Screening
- Subjects participating in, or scheduled for, an intensive COPD rehabilitation program (subjects who are in the maintenance phase of a rehabilitation program are eligible to take part)
- Current diagnosis of asthma according to Global Initiative for Asthma guidelines
- Previous treatment with MEDI-563.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo
Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
|
Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
|
Expérimental: Benralizumab 100 mg
Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
|
Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Délai: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
Annualized Incidence Rate of Moderate or Severe AECOPD was assessed based on AECOPD data up to Day 393 (Rate = total number of moderate or severe AECOPD in each group/total person-year follow-up in each group).
The severity of an exacerbation of COPD is defined as: a) Mild exacerbations, which require treatment with an increase in usual therapy, example (eg), increase use of short acting bronchodilators, b) Moderate exacerbations which require treatment with systemic corticosteroids, and or antibiotics and c) Severe exacerbations which require hospitalization.
|
Day 1 up to 393
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Délai: Day 1 up to 561
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between administration of study drug and up to Day 561 that were absent before treatment or that worsened relative to pre-treatment state.
TEAEs reported below included both SAEs and non-serious AEs.
|
Day 1 up to 561
|
Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Délai: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
|
Day 1 up to 393
|
Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Délai: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
|
Day 1 up to 393
|
Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Délai: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
Annualized Incidence Rate of hospitalization due to AECOPD was calculated as Rate = total number of hospitalizations/ total person years.
|
Day 1 up to 393
|
Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393
Délai: Baseline, Day 393
|
The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
|
Baseline, Day 393
|
Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score
Délai: Day 393
|
SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score were derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
Percentage of participants with 4-point, 8-point and 12-point change from baseline in SGRQ-C total score were observed.
|
Day 393
|
Change From Baseline in Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Domain Scores at Day 393
Délai: Baseline, Day 393
|
The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items).
Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment).
Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment).
|
Baseline, Day 393
|
Percentage of Participants With a 0.5-Point Improvement in Chronic Respiratory Questionnaire Self-administered Standardized Format (CRQ-SAS) Domain Scores at Day 393
Délai: Day 393
|
The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items).
Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment).
Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment).
Participants with 0.5 point improvement from baseline in the domain scores were observed.
|
Day 393
|
Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Scores at Day 393
Délai: Baseline, Day 393
|
The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test.
The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe ).
BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).
|
Baseline, Day 393
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Rene van der Merwe, MBChB, MedImmune Ltd
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8.
- Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 novembre 2010
Achèvement primaire (Réel)
1 janvier 2013
Achèvement de l'étude (Réel)
1 juillet 2013
Dates d'inscription aux études
Première soumission
21 octobre 2010
Première soumission répondant aux critères de contrôle qualité
22 octobre 2010
Première publication (Estimation)
25 octobre 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
5 octobre 2016
Dernière mise à jour soumise répondant aux critères de contrôle qualité
11 août 2016
Dernière vérification
1 mars 2015
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MI-CP196
- 2010-020127-52 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
Regado Biosciences, Inc.ComplétéVolontaire en bonne santéÉtats-Unis